Anavex Life Sciences Corp.
AVXL
$4.31
-$0.27-5.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.95M | 13.05M | 11.34M | 11.62M | 11.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.76M | 53.50M | 53.25M | 52.98M | 50.59M |
| Operating Income | -50.76M | -53.50M | -53.25M | -52.98M | -50.59M |
| Income Before Tax | -46.38M | -48.17M | -47.14M | -46.49M | -43.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -46.38 | -48.17 | -47.14 | -46.49 | -43.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.38M | -48.17M | -47.14M | -46.49M | -43.00M |
| EBIT | -50.76M | -53.50M | -53.25M | -52.98M | -50.59M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.54 | -0.57 | -0.56 | -0.55 | -0.51 |
| Normalized Basic EPS | -0.34 | -0.35 | -0.35 | -0.35 | -0.32 |
| EPS Diluted | -0.54 | -0.57 | -0.56 | -0.55 | -0.51 |
| Normalized Diluted EPS | -0.34 | -0.35 | -0.35 | -0.35 | -0.32 |
| Average Basic Shares Outstanding | 341.15M | 340.06M | 339.21M | 336.60M | 333.87M |
| Average Diluted Shares Outstanding | 341.15M | 340.06M | 339.21M | 336.60M | 333.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |